Literature DB >> 32109226

Analysis of Risk Factors for Anorectal Stenosis of Perianal Fistulizing Crohn's Disease.

MinMin Xu1, BoLin Yang1, HongJin Chen2, YunFei Gu2, YouRan Li1.   

Abstract

BACKGROUND To analyze the risk factors of anorectal stenosis associated with perianal fistulizing Crohn's disease (PFCD). MATERIAL AND METHODS We retrospectively analyzed 139 cases of PFCD from January 2010 to December 2017 at the Affiliated Hospital of Nanjing University of Chinese Medicine. They were divided into 2 groups according to whether anorectal stenosis occurred. The possible factors associated with anorectal stenosis of PFCD were selected based on the literature review and clinical observations. Univariate analysis was performed to screen the risk factors of anorectal stenosis, and multivariate logistic regression analysis was performed on these risk factors and factors that were clinically considered to be potentially influential, to screen out the independent risk factors of anorectal stenosis. RESULTS We found that 44 cases (31.7%) of PFCD were associated with anorectal stenosis. Univariate analysis showed that CDAI, lesion location, and age at diagnosis were risk factors for anorectal stenosis of PFCD. Logistic regression analysis showed that mild (fair to good) (OR=3.833, 95% CI: 1.123~13.080) to moderate (poor) (OR=7.345, 95% CI: 1.964~27.474) CDAI and age at diagnosis (OR=1.067, 95% CI: 1.013~1.124) were independent risk factors for anorectal stenosis of PFCD. CONCLUSIONS Higher CDAI and older age at diagnosis appear to confer higher risk of anorectal stenosis associated with PFCD.

Entities:  

Mesh:

Year:  2020        PMID: 32109226      PMCID: PMC7063846          DOI: 10.12659/MSM.920243

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Anal fistula is the most common perianal Crohn’s disease (CD); about 35% of CD patients are complicated with anal fistula [1], and it is the initial symptom in 5% of CD patients [2]. We analyzed the data on perianal fistulizing Crohn’s disease (PFCD) from January 2010 to December 2017 in the Department of Colorectal Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine (AHNUCM), and found that among 139 PFCD cases, 44 cases (31.7%) were complicated with anorectal stenosis, which exceeded the incidence rates of other complicated perianal lesions (such as verrucous dermatophytes, anal fissure, abscess and rectovaginal fistula) [3]. There is an abundance of literature on PFCD, but data on other types of perianal CD remain scarce. The epidemiological investigation of anorectal stricture in CD has not been reported. Fibrotic anorectal stricture in CD usually occurs as a result of chronic inflammation and often occurs late in the course of the disease [4]. Anorectal stenosis affects defecation functions, and even requires fecal diversion in severe cases. It has a severe impact on patients’ daily life. In an attempt to minimize the incidence of anorectal stenosis of PFCD, we analyzed the clinical data of 139 cases to identify potential influencing factors.

Material and Methods

Data collection

In our research center, specialized Inflammatory Bowel Disease medical staff registered basic information such as sex, age, body mass index (BMI), asked for medical history such as CD course, anal fistula course, clinical symptoms, abdominal surgery history, perianal surgery history, and medication history, and performed examinations such as endoscopy, imaging, and laboratory tests of patients with PFCD who were hospitalized. These medical staff were trained to evaluate the patients according to the diagnostic criteria, clinical evaluation, and classification criteria. We recorded data on Montreal classification, anal fistula type, number of external openings, concomitant perianal lesions, CD activity index (CDAI), perianal disease activity index (PDAI) and some laboratory indexes. We retrospectively analyzed the data of 139 cases of PFCD, who were hospitalized for the first time at the Department of Colorectal Surgery of AHNUCM from January 2010 to January 2017. The clinical information is shown in Table 1. The patients were divided into 2 groups according to whether anorectal stenosis occurred, and then statistical analysis was conducted. This study conformed to the Helsinki Declaration and we obtained informed consent from all patients. The study was approved by the Ethics Committee of AHNUCM (approval number of 2017NL-071-02).
Table 1

Patient characteristics.

ItemN (%)ItemN (%)
SexNumber of external openings
 Male107 (77.0) 148 (34.5)
 Female32 (23.0) 244 (31.7)
BMI (kg/m2) ≥347 (33.8)
 <18.563 (45.3)Concomitant perianal diseases
 18.5~23.964 (46.0) Anorectal stenosis44 (31.7)
 ≥2412 (8.7) Fissure6 (4.3)
previous abdominal surgery (no. of times) Abscess33 (23.7)
123 (16.5) Rectovaginal fistula7 (5.0)
>14 (2.9) Verrucous skin43 (30.9)
History of perianal surgeryDiagnostic age (years)
 Anal fistula surgery38 (27.3) ≤16 (A1)6 (4.3)
 Perianal abscess surgery56 (40.3) 17~40 (A2)119 (85.6)
 Hemorrhoids surgery6 (4.3) >40 (A3)14 (10.0)
 Anal fissure surgery2 (1.4)Location of lesion
 Excision of perianal masses1 (0.7) Ileum (L1)33 (23.7)
Previous perianal surgery (no. of times) Colon (L2)37 (26.6)
 158 (41.7) Ileocolon (L3)69 (49.6)
 >132 (23.0)Disease behavior
Medication history Nonstricturing nonpenetrating (B1)72 (51.8)
 5-ASA62 (44.6) Stricturing (B2)57 (41.0)
 SASP15 (10.8) Stricturing and penetrating (B2B3)10 (7.2)
 Immunosuppressor24 (17.3)CDAI
 Corticosteroid31 (22.3) Very well (<150 points)49 (35.3)
 Biologics22 (15.8) Fair to good (150~220 points)53 (38.1)
 Antibiotic16 (11.5) Poor (221~450 points)37 (26.6)
 Enteral nutrition28 (20.1) Very poor (>450 points)0 (0)
 Elsea23 (16.5)PDAI
 None37 (26.6) Remission stage (≤4 points)8 (5.6)
CD course (year) Active stage (>4 points)131 (94.2)
 <178 (56.1)CRP (mg/L)
 1~542 (30.2) <886 (61.9)
 >519 (13.7) ≥853 (38.1)
Anal fistula course (year)ESR (mm/h)
 <174 (53.2) Above normal74 (53.2)
 1~550 (36.0) Normal65 (46.8)
 >515 (10.8)Hb (g/L)
Relationship between the 2 courses Below normal54 (38.8)
 Anal fistula appeared first66 (47.5%) Normal85 (61.2)
 Simultaneous27 (19.4%)PLT (×109/L)
 Intestinal inflammation appeared first46 (33.1%) <1001 (0.7)
Clinical symptoms 100~30088 (63.3)
 Diarrhea64 (46.0) ≥30050 (36.0)
 Perianal symptoms only41 (29.5)WBC (×109/L)
 Loss of weight37 (26.6) <411 (7.9)
 Abdominal pain30 (21.6) 4~10115 (82.7)
 Fever27 (19.4) >1013 (9.4)
 Hematochezia23 (16.5)Alb (g/L)
 Anemia21 (15.1) <3533 (23.7)
Anal fistula type 35~50103 (74.1)
 Simple13 (9.4) >503 (2.2)
 Complex126 (90.6)

CDAI – CD activity index; PDAI – perianal disease activity index; CRP – C-reactive protein; ESR – erythrocyte sedimentation rate; WBC – leukocyte, PLT – platelet; HB – hemoglobin; Alb – albumin. a: Refers to treatment with Chinese herbal medicine, extract of Chinese herbal medicine, transplantation of fecal bacteria, anti-tuberculosis, and antiviral treatment.

Diagnostic criteria

The diagnostic criteria for PFCD referred to “A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulizing Crohn’s disease” published in 2014 by the World Gastroenterology Organization [5]. The diagnostic criteria of anorectal stenosis referred to “diagnostic basis, syndrome classification, and efficacy evaluation of anorectal stenosis” in “Criteria for the diagnosis and treatment of diseases and syndromes in internal medicine of traditional Chinese medicine” (ZY/T001.1-94), which is the Chinese medicine industry standard of the People’s Republic of China [6]. Anorectal stenosis referred to the narrowing of the anal and rectal passages caused by any reason and leading to defecation difficulties. It was diagnosed based on difficult defecation, a history of perianal inflammation, anal injury or anorectal surgery, and index finger difficulty on examination.

Clinical evaluation and classification criteria

The nutritional status of the patients was assessed by BMI [7], with 18.5~23.9 as normal and <18.5 and ≥24 as abnormal. The classification of CD was conducted using the Montreal Phenotypic Classification proposed by the World Gastroenterology Working Group in 2005 [8], which includes age (A), lesion site (L), and disease behavior (B). In this study, B2 type included anorectal stenosis, and B3 type excluded the penetration caused by anal fistula. The Best CDAI algorithm [9] was used to evaluate the activity index of CD: <150 points, very well;150~220 points, fair to good; 221~450 points, poor; >450, very poor. PDAI was used to evaluate the activity of PFCD [10]: ≤4 indicating remission stage and >4 indicating active stage. Classification of anal fistulas referred to the American Gastroenterological Association’s medical position statement about perianal Crohn’s disease in 2003 [11], and divided into simple anal fistula and complex anal fistula. Simple anal fistula refers to a low (superficial fistula, low inter-sphincteric or trans-sphincter fistula), single, external opening, with no abscess signs such as pain or fluctuation, no rectovaginal fistula, and no anorectal stenosis, whereas complex anal fistula refers to the opposite.

Statistical analysis

SPSS 23.0 software was used for statistical analysis. The group chi-square test and likelihood ratio test were used for enumeration data. Unconditional logistic regression analysis was used for multiple factor analysis. The test level was α=0.05.

Results

Univariate analysis

Patients were divided into 2 groups according to whether accompanied anorectal stenosis occurred, and all variables that might cause anorectal stenosis on the basis of literatures review and clinical observation were analyzed. Univariate analysis was conducted on these clinical data to screen out the factors influencing anorectal stenosis of PFCD. Since we classified anorectal stenosis into B2, which was related to disease behavior, we did not include disease behavior into the univariate analysis objects. Univariate analysis results showed that CDAI (p<0.001), lesion location (p=0.019), and age at diagnosis (p=0.037) are risk factors for anorectal stenosis of PFCD, while CRP level, sex, number of external openings, BMI, PDAI status, corticosteroid usage, previous medication, biologics therapy history, combination therapy history, previous perianal surgery history, previous abdominal surgery history, anal fistula course and CD course were unrelated (p>0.05) (Table 2).
Table 2

Univariate analysis of anorectal stenosis of PFCD.

Clinical featuresTotal NWithout anorectal stenosisN=95With anorectal stenosisN=44χ2 valueP value
CRP (mg/l)1.0870.297
 <85339 (73.6)14 (26.4)
 ≥88656 (65.1)30 (34.9)
Sex0.2390.625
 Male10772 (70.6)35 (32.7)
 Female3223 (67.3)9 (28.1)
External opening number1.5460.462
 14836 (75.0)12 (25.0)
 24429 (65.9)15 (34.1)
 ≥34730 (63.8)17 (36.2)
BMI (kg/m2)2.946*0.244
 18.5~23.96446 (71.9)18 (28.1)
 <18.56339 (61.9)24 (38.1)
 ≥24.01210 (83.3)2 (16.7)
CDAI19.433<0.001
 Very well4944 (89.8)5 (10.2)
 Fair to good5334 (64.2)19 (35.8)
 Poor3717 (45.9)20 (54.1)
PDAI1.683*0.195
 Remission stage87 (87.5)1 (12.5)
 Active stage13188 (67.2)43 (32.8)
Previous perianal surgery0.0380.845
 Yes4934 (69.4)15 (30.6)
 No9061 (67.8)29 (32.2)
Previous abdominal surgery2.0340.154
 Yes11179 (71.2)32 (28.8)
 No2816 (57.1)12 (42.9)
Anal fistula course (year)3.9940.136
 <17454 (73.0)20 (27.0)
 1–55034 (68.0)16 (32.0)
 >5157 (46.7)8 (53.3)
CD course (year)4.8930.087
 <17859 (75.6)19 (24.4)
 1–54226 (61.9)16 (38.1)
 >51910 (52.6)9 (47.4)
Location of lesion7.9350.019
 L13327 (81.8)6 (18.2)
 L23719 (51.4)18 (48.6)
 L36949 (71.0)20 (29.0)
Age at diagnosis6.609*0.037
 A166 (100)0 (0)
 A211982 (68.9)37 (31.1)
 A3147 (50.0)7 (50.0)
Previous medication3.7800.052
 Yes10265 (63.7)37 (36.3)
 No3730 (81.1)7 (18.9)
Previous corticosteroid therapy0.0070.935
 Yes3121 (67.7)10 (32.3)
 No10874 (68.5)34 (31.5)
Previous biologics therapy2.1930.139
 Yes2218 (81.8)4 (18.2)
 No11777 (65.8)40 (34.2)
Previous combination therapy1.0380.308
 Yes6743 (64.2)24 (35.8)
 No7252 (72.2)20 (27.8)

Likelihood ratio test.

Multivariate logistic regression

Multivariate logistic regression analysis was conducted on the risk factors detailed above and variables that were clinically considered to be potentially influential to determine the independent risk factors of anorectal stenosis of PFCD. The results showed that mild (fair to good) (OR=3.833, 95% CI: 1.123~13.080) to moderate (poor) (OR=7.345, 95% CI: 1.964~27.474) CDAI and age at diagnosis (OR=1.067, 95% CI: 1.013~1.124) were independent risk factors for anorectal stenosis of PFCD (Table 3).
Table 3

Multivariate logistic regression analysis of anorectal stenosis of PFCD.

ItemB valueWald χ2 valuedfP valueOR value95% CI
Lower limitUpper limit
Location of lesion2.07320.361
 L20.4770.48210.4871.6120.4196.197
 L3−0.2250.13010.7190.7990.2342.719
CD course (years)0.23520.889
 1–50.0020.00010.9970.9980.3562.797
 >5−0.2950.18810.6650.7450.1962.827
CDAI8.78120.012
Fair to good1.3444.60210.0323.8331.12313.080
Poor1.9948.77710.0037.3451.96427.474
Diagnostic age0.0655.97910.0141.0671.0131.124
CRP (≥8 mg/l)0.2260.22910.6321.2530.4973.160
PDAI0.0520.49510.4821.0530.9121.216
Previous medication (yes)0.6351.00010.3171.8870.5436.555
Constant−4.95515.89710.0000.007

Age at diagnosis and PDAI were included as continuous variables.

Treatment of patients with anorectal stenosis

We found that 86.4% (38 patients) of these anorectal stenosis patients received medication prior to the diagnosis of anorectal stenosis, and 4 of them had received biologic therapy previously (Table 2). After the diagnosis of anorectal stenosis, these patients received anal dilatation or medication according to the component of the stenosis; 80% of them received dilatation under anesthesia because of fibrotic stenosis, and the others received a biologic agent or immunosuppressor because of inflammatory stenosis.

Discussion

Perianal CD and location of intestinal lesion

The incidence of perianal CD is closely related to the location of intestinal lesions, and it is significantly increased when inflammation involves the rectum [12,13]. Anal fistula is associated with 12% of isolated ileal CD, 15% of ileal colon CD, 41% of colon CD when the rectum is not involved, and 92% of colon CD when the rectum is involved, and only 5% CD patients initially present with an anal fistula without any intestinal inflammation [14,15]. Although the European Crohn’s and Colitis Organization (ECCO) Consensus did not elaborate on the relationship between anorectal stenosis occurrence and intestinal inflammation location, our study showed that the anorectal stenosis incidence rate of colonic CD (48.6%) was higher than of ileac CD (18.2%) and ileocolic CD (29.0%), and the difference was statistically significant (P=0.019). Therefore, we speculated that incidence of anal fistula and anal anorectal stenosis of CD was correlated with distal intestinal lesions. The development of CD itself can lead to damage to the internal and external sphincter and perineal body, and proctitis leads to decreased rectal compliance. Even a moderate level of sphincter function decline can eventually result in incontinence due to decreased colonic absorption of water, rectal capacity, and compliance. The only surgical method for anal fistula of CD complicated with proctitis is seton drainage, and deterministic surgical methods to promote fistula closure are not feasible [5]. When the anorectal stenosis is associated with proctitis, anal dilatation often leads to inflammation tissue bleeding, so medical treatment to control proctitis should be the first choice. Anal dilatation and sternotomy are more suitable for patients with fibrous stenosis. If the stenosis is extensive, it is difficult for patients to avoid bypass surgeries.

Anal fistula, anorectal stenosis, and intestinal inflammatory activity in CD

Previous studies showed that the risk factors of perianal lesions in CD are related not only to lesion location [16-18], but also to sex, age, and race. However, no correlation between the incidence of CD perianal lesions and intestinal inflammatory activity has been reported. The results of the present study suggest that higher CDAI is associated with higher the risk of anorectal stenosis, meaning that the severity of intestinal inflammation of CD can directly affect the incidence of rectal stenosis. Most CD patients are initially diagnosed on the basis of pathological changes in inflammation. When diagnosed, only one-third of patients have evidence of stenosis or penetration. After chronic relapses, the inflammatory disease phenotype tends to shift to a stenosis and/or penetrating phenotype, characterized by serious complications such as stenosis or fistula. Epithelial mesenchymal transformation (EMT) is involved in tissue healing in response to traumas. When a tissue or organ is injured, it triggers a complex chain of healing reactions. This delicate process of tissue repair is important for stability of the internal environment of organs. However, the imbalance between excessive and inadequate tissue repair can impair organ function, with ulceration and fistula formation on the one hand, and fibrosis and stenosis on the other [19]. EMT seems to be the driving force for the development of fistulas and the key to the development of fibrosis [20,21]. In this study, 31.7% of PFCD patients were complicated with rectal stenosis, more than with other complications, which confirms the theory that the mechanisms of development of anal fistula and fibrosis are similar. There is evidence showing that intestinal inflammation is the main driver of CD fibrosis [22,23]. This evidence may also explain our observation that higher CDAI is associated with greater risk of rectal stenosis. In this study, the patients who had previously received medication had higher incidence of rectal stenosis (p=0.052), although the difference was not statistically significant. Why did the medication fail to control inflammation but lead to a higher incidence of stenosis? This may be related to the longer course of CD in these patients; 74 of the 102 patients who had previous medication had a CD course of more than 1 year. Inflammatory or fibrous stenosis can develop due to long-term inflammation under inappropriate medication.

Age and anorectal stenosis in CD

Cosnes et al. [18] reported that CD patients under the age of 40 years had a higher incidence of perianal lesions, but this study showed that the incidence of anorectal stenosis increased by 6.1% for each additional year of age, meaning that older age is associated with higher incidence of anorectal stenosis, which is inconsistent with the data we found in our literature review. The reason may be that the age of patients in this group was age at diagnosis. The experience and proficiency of physicians prescribing CD treatment can enormously affect the time span from onset to diagnosis. A longer course of disease could mean older age at diagnosis and longer development of inflammation, and longer development of inflammation can lead to increased incidence of perianal lesions. In this group, the incidence of anorectal stenosis of patients with a disease course longer than 5 years was 47.4%, which is higher than the 38.1% of patients with 1–5 years and the 24.4% of patients with less than 1 year. Although the difference was not statistically significant, the influence of course of disease on the incidence of anorectal stenosis can be preliminarily speculated.

Conclusions

In conclusion, the lesion location, degree of intestinal inflammation, and age at diagnosis of CD patients all affect the occurrence of anorectal stenosis. Especially, the degree of intestinal inflammation and age at diagnosis are independent risk factors for the occurrence of anorectal stenosis. Our findings suggest that higher CDAI and older age at diagnosis are associated with higher risks of anorectal stenosis associated with PFCD. For medical personnel, it is important to choose personalized therapeutic plans, control the intestinal inflammatory activity of patients, and achieve early diagnosis and early treatment to prevent the occurrence of anorectal stenosis. In future research, we plan to assess the long-term outcomes of anorectal stenosis to determine what factors influenced the outcome.
  22 in total

1.  European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.

Authors:  R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

2.  A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease.

Authors:  Krisztina B Gecse; Willem Bemelman; Michael A Kamm; Jaap Stoker; Reena Khanna; Siew C Ng; Julián Panés; Gert van Assche; Zhanju Liu; Ailsa Hart; Barrett G Levesque; Geert D'Haens
Journal:  Gut       Date:  2014-06-20       Impact factor: 23.059

3.  Perianal Crohn's disease. Results of local surgical treatment.

Authors:  Y P Sangwan; D J Schoetz; J J Murray; P L Roberts; J A Coller
Journal:  Dis Colon Rectum       Date:  1996-05       Impact factor: 4.585

Review 4.  Anoperineal lesions in Crohn's disease: French recommendations for clinical practice.

Authors:  D Bouchard; L Abramowitz; G Bouguen; C Brochard; A Dabadie; V de Parades; M Eléouet-Kaplan; N Fathallah; J-L Faucheron; L Maggiori; Y Panis; F Pigot; P Rouméguère; A Sénéjoux; L Siproudhis; G Staumont; J-M Suduca; B Vinson-Bonnet; J-D Zeitoun
Journal:  Tech Coloproctol       Date:  2017-09-19       Impact factor: 3.781

5.  Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease.

Authors:  Britta Siegmund; Roger M Feakins; Giorgos Barmias; Juliano Coelho Ludvig; Fabio Vieira Teixeira; Gerhard Rogler; Michael Scharl
Journal:  J Crohns Colitis       Date:  2015-12-17       Impact factor: 9.071

6.  [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].

Authors:  Piotr Rozpondek; Małgorzata Zwolińska-Wcisło; Magdalena Przybylska; Tomasz Mach
Journal:  Przegl Lek       Date:  2011

7.  Are perineal and luminal fistulas associated in Crohn's disease? A population-based study.

Authors:  Linda Y Tang; Patricia Rawsthorne; Charles N Bernstein
Journal:  Clin Gastroenterol Hepatol       Date:  2006-08-14       Impact factor: 11.382

8.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

Review 9.  Epithelial-mesenchymal transition and its implications for fibrosis.

Authors:  Raghu Kalluri; Eric G Neilson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

10.  Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis.

Authors:  Michael Scharl; Nicole Huber; Silvia Lang; Alois Fürst; Ekkehard Jehle; Gerhard Rogler
Journal:  Clin Transl Med       Date:  2015-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.